BioMarin Clinical Trials logo
  • Guide to Clinical Trials
    • Understanding Clinical Trials
    • Our Commitment
    • FAQs
  • Areas of Clinical Research
    • Achondroplasia
    • Alpha-1 Antitrypsin Deficiency
    • Duchenne Muscular Dystrophy
    • Hypochondroplasia
    • Idiopathic Short Stature
    • Noonan Syndrome
    • Phenylketonuria
    • SHOX Deficiency
    • Turner Syndrome
  • HCP
  • BioMarin.com
Contact
  • Contact

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a progressive neuromuscular condition caused by a deficiency in dystrophin, an essential protein in muscle fibers. It mostly affects boys, with onset of symptoms around 2 to 3 years of age.

Learn more about our active Duchenne muscular dystrophy clinical trials below. To view all BioMarin’s historical trials in Duchenne muscular dystrophy, click here.

Duchenne Muscular Dystrophy Clinical Trials

NCT06280209

Trial Status Recruiting

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants with Duchenne Muscular Dystrophy

Learn More

Print

Understanding Clinical Trials

Mother and child sit opposite a doctor at a desk

Our Commitment

Miranda Newquist in San Rafael Lab

Frequently Asked Questions

HCP filling out paperwork

You're leaving the BioMarin Clinical Trials website.

This will take you to BioMarin.com, our global corporate website. Some of the information on BioMarin.com is intended for U.S. audiences only.

Leave this website Close

You’re leaving the BioMarin Clinical Trials website.

Links to sites outside of this website are provided as a resource to the viewer. BioMarin accepts no responsibility for the content of linked sites.

Leave this website Close

BioMarin Clinical Trials logo
  • Privacy Policy
  • Terms of Use
  • Supply Chain Statement
  • Report an Adverse Event
  • Cookie Settings
  • LinkedIn
  • X
  • Instagram
  • Facebook

© 2025 BioMarin. All rights reserved. MMRC-MPRL-00150 03/25